Issue 48, 2023

Polymorphism of amantadinium niflumate

Abstract

Two polymorphs of amantadinium niflumate were obtained as new forms of potential medicine combining niflumic acid – a non-steroidal anti-inflammatory drug, with amantadine – a drug used in the treatment of Parkinson's disease. The polymorphs were structurally characterized showing the differences in crystal packing and intermolecular interactions. Interactions were analyzed in both crystals by theoretical methods: quantum theory of atoms in molecules (QTAIM) and noncovalent interaction (NCI) approaches.

Graphical abstract: Polymorphism of amantadinium niflumate

Supplementary files

Article information

Article type
Paper
Submitted
28 Jul 2023
Accepted
05 Nov 2023
First published
23 Nov 2023

CrystEngComm, 2023,25, 6748-6757

Polymorphism of amantadinium niflumate

M. S. Krawczyk, M. K. Krawczyk and I. Majerz, CrystEngComm, 2023, 25, 6748 DOI: 10.1039/D3CE00754E

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements